Torrent Pharmaceuticals has recently announced its plans to acquire three anti-diabetes brands from Boehringer Ingelheim GmbH in Germany. This move is expected to strengthen Torrent's portfolio in the diabetes treatment market.

Torrent has been co-marketing these products since 2022 under an existing agreement with Boehringer Ingelheim India. The news of the acquisition has generated interest in Torrent's shares, which are currently trading at ₹3,352.65, reflecting a slight decline of 0.31% with a trading volume of 419,534.

Investors will be closely watching the developments surrounding this acquisition as it could impact Torrent's market position and growth in the pharmaceutical sector.

• The brands involved in the acquisition are Cospiaq, Cospiaq Met, and Xilingio.

The acquisition is set to be completed by March 2025.